GlassScriptPhysician profile
Elise J Landa
NPI 1679923155
$3,438.28
in general payments reported to CMS, 2019-2025
26 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,219 · 2020: $240 · 2021: $444 · 2022: $331 · 2023: $309 · 2024: $581 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.62 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,170.79 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $351.11 | 2019-2021 | |
| Pulmonx Corporation | $345.24 | 2020-2024 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Astrazeneca Pharmaceuticals LP | $221.51 | 2021-2024 | Fasenra, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $193.39 | 2019 | |
| Inari Medical, INC. | $178.89 | 2022 | |
| United Therapeutics Corporation | $146.00 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $120.16 | 2023-2024 | Dupixent |
| Genzyme Corporation | $114.84 | 2019-2024 | |
| Mallinckrodt Enterprises LLC | $99.06 | 2019 | |
| Verona Pharma, INC. | $86.94 | 2025 | Ohtuvayre |
| Harmony Biosciences LLC | $53.33 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $45.93 | 2020 | |
| Merck Sharp & Dohme LLC | $44.34 | 2023 | Verquvo |
| Csl Behring | $39.07 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $34.00 | 2025 | |
| Jazz Pharmaceuticals INC. | $31.81 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.07 | 2025 | |
| Resmed Corp | $22.56 | 2023 | |
| Novo Nordisk INC | $21.68 | 2021 | |
| Mylan Specialty L.P. | $18.77 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.29 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.40 | 2024 | Glassia |
| Gilead Sciences, INC. | $14.07 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.66 | 2019 | |
| Electromed, INC. | $13.37 | 2024 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elise Landa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.